key: cord-1038846-jv2ybe06
authors: Ghosh, Ritwik; Dubey, Souvik; Roy, Dipayan; Ray, Adrija; Pandit, Alak; Ray, Biman Kanti; Benito-León, Julián
title: Choreo-ballistic movements heralding COVID-19 induced diabetic ketoacidosis
date: 2021-04-23
journal: Diabetes Metab Syndr
DOI: 10.1016/j.dsx.2021.04.010
sha: 628a419e2752969a67e9a6cbb5ace09ce75ebf96
doc_id: 1038846
cord_uid: jv2ybe06

nan

well established. 1, 2 This dangerous duo has an established bidirectional relationship. 3 Diabetic ketoacidosis (DKA) is a severe acute metabolic complication typically characterized by acidosis, ketosis and usually hyperglycaemia. 4 There are several reported cases of previously euglycemic, undiagnosed, pre-diabetic or controlled diabetic patients who presented with DKA after harboring COVID-19. 1, 2 Several pathogenic mechanisms have been proposed for the development of insulinopenia, decreased insulin sensitivity, and increased insulin resistance in the backdrop of severe acute respiratory syndrome-coronavirus (SARS-CoV-2) infection. [1] [2] [3] Chorea and ballism are well-recognized, acute onset and potentially reversible movement disorders in acute hyperglycemic surges, especially in hyperosmolar hyperglycemic states (HHS), 5 but rarely in DKA. 6 On the other hand, de novo movement disorders are scantly reported in COVID-19. 7 We hereby describe the first case of a previously non-diabetic healthy patient who acutely presented with choreo-ballistic movements as the initial manifestation of COVID-19 induced DKA. Albeit, evidently COVID-19 induced diabetic striatopathy seems to be the most acceptable etiopathogenic milieu, 6 possibility of de novo appearance of a movement disorder solely due to the viral infection itself remains alive.

A 60-year-old previously non-diabetic healthy man from rural India was admitted as he experienced sudden onset involuntary, uncontrollable, abnormal movements affecting his right arm and right leg for the last 36 hours. He also complained of dull aching pain in his abdomen J o u r n a l P r e -p r o o f for last 3 days associated with fever, cough, throat ache, malaise, increased thirst, excessive frequency of urination, and generalized weakness. His past medical history and drug history were unrevealing, and all vital signs were normal except fever. Neurological examination for SARS-CoV-2, by qualitative real-time reverse-transcriptase-polymerase-chain-reaction assay, was positive, meanwhile, capillary blood glucose was 540 mg/dL (tested at bedside).

Dipstick urinalysis was suggestive of ketonuria (aceto-acetate). Complete hemogram, liver and thyroid function tests, serum electrolytes, cardiac troponins, lipase, electrocardiography, chest Xray and abdominal ultrasound were normal except mild neutrophilic leukocytosis (13000/μl) and lymphopenia (15%) as well as increased erythrocyte sedimentation rate (50 mm/hour) and Creactive protein (58 mg/L). Blood and urine cultures failed to demonstrate any hint of bacterial infections. HbA1c was 5.1% (by HPLC, NGSP certified method). Type-1 diabetes autoimmune panel (serum GAD-65, anti-IA-2, insulin antibodies and islet cell antibodies) was negative. Rehydration with intravenous fluids and continuous intravenous insulin infusion was initiated. Since respiratory symptoms were mild and high resolution computed tomography scan of the thorax was normal, he was not put on any specific therapy for the infection per se. After two days, ketonuria, ketonemia and acidemia disappeared and blood glucose level stabilized (capillary blood glucose was kept in the range 140-180 mg/dL) for which the insulin regime was shifted to the subcutaneous route after initial bridging with infusion regime. The abnormal movements abated with sustained normalization of blood glucose levels. He was discharged after seven days with a basal-bolus regime of insulin (insulin glargine (300 U/ml) 20 U/day subcutaneously as single basal therapy and 12 IU of soluble insulin (40 IU/ml) before breakfast, lunch and dinner) and diabetic medical nutrition therapy. Figure 2 summarizes the timeline of events. He is continuously being followed up at regular intervals with achievement of good glycemic control and no evidence of recurrence of neurological ailments. It is worth mentioning that with each follow-up, total insulin requirement was showing a gradual yet definite downtrend; fasting serum C-peptide level at sixth month of follow-up was 0.86 ng/ml (normal J o u r n a l P r e -p r o o f 0.81-3.85). Since seventh month of follow-up, he is maintaining euglycemic state with insulin glargine (300 U/ml, single 14 U/day dose, subcutaneously) and soluble insulin (40 IU/ml, 6 IU subcutaneously 30 min before each major meal i.e. breakfast, lunch and dinner). Third, virus-triggered "autoimmune insulitis". Fourth, it might be an inflammation-induced insulin resistance. Fifth, renin-angiotensin-aldosterone system activation and reactive oxygen species over-production. Sixth, IL-6, elevated in COVID-19, may be a driver for ketosis.

Seventh, exogenous glucocorticoids for combating cytokine storm in COVID-19 worsens glycemic control. Eighth, SARS-CoV-2 itself might have the potential for the development of type-1 diabetes like other viruses such as cytomegalovirus, Epstein-Barr virus, rotavirus, mumps, rubella, coxsackieviruses, enterovirus, and hepatitis C virus, among others. 12 First, second and fourth mechanisms separately or together might have played a role in this case. The striatum is a vulnerable region to acute metabolic perturbations due to both vascular and direct neuronal (dopaminergic and glutamatergic excitotoxicity) insults. 13 Diabetic striatopathy is one of the remarkably rare and reversible disorders in which an episode of acute hyperglycemia precipitates J o u r n a l P r e -p r o o f a transient, usually self-limiting movement disorder, with specific findings on neuroimaging involving striatum, having a particular predilection for elderly Asians. 6, 8 Although this entity is increasingly being reported in hyperosmolar hyperglycemic states , it is rare in DKA, possibly due to the underlying pathological differences between the two. 14 Anaerobic cerebral metabolism in hyperglycemia leads to the depletion of gamma-amino-butyric acid (GABA) resulting in globus pallidus interna (GPi) mediated thalamic disinhibition, further culminating into hyperkinetic movement disorders. 6, 8, 14 Medical literature on "diabetic striatopathy" divulges that altered GABA metabolism in brain cells, hyperviscosity, cytotoxicity, obliterative vasculopathy, and hyperglycemia itself might lead to neuronal loss due to gemistocyte accumulation in the striatum, which can be considered as the genesis behind movement disorders. 6, 15 However, this might not explain hyperkinetic movements in DKA as there exists an adequate supply of GABA (ketosis helps in resynthesizing this neurotransmitter in the liver from acetoacetate). 14 Evidence suggests that SARS-CoV-2 infects the astrocytes and triggers neuropathological changes. 16 Specifically, a LC/MS-based metabolomic analysis has revealed extensive glycolytic changes and anaplerotic reactions, including a decrease in pyruvate, lactate, glutamine, glutamate and GABA in the brain of COVID-19 patients. 16 Therefore, increased metabolic activity of the SARS-CoV-2 infected cells, as well as a decrease in essential metabolites, especially glutamine and glutamine metabolism intermediates, may be responsible for affecting neuronal functionsand the genesis of movement disorders (Figure 3 ). 16 Further, the presence of the virus has also been associated with astrogliosis and immune cell accumulation, pointing towards immune-mediated neurodegeneration (Figure 3 ). 16 We feel that both DKA and SARS-CoV-2 could have jointly contributed to the genesis of movement disorders. Also, the viral infection could have precipitated DKA and striatopathy that J o u r n a l P r e -p r o o f favored the movement disorders. 14 SARS-CoV-2 infection could also lead to depletion of GABA, which caused GPi-mediated thalamic disinhibition and resultant choreo-ballistic movements. These interconnections might well be one of the appropriate explanations for the apparent clinical-radiological discordance in this case, i.e. clinical presence of a ballistic movement disorder in absence of any demonstrable lesion over sub-thalamic nucleus or thalamus on MRI rather lesion was seen predominantly over caudate, putamen and globus pallidus.

Gradual downtrend in requirement of insulin for maintenance of euglycemia and relative normalization of C-peptide level might be suggestive of gradual recovery from "glucotoxicity", decreasing insulin resistance that was associated with infection and inflammation, increasing insulin sensitivity, or rejuvenation of islet cells from infection/inflammation related transient dormancy.

To conclude, our case shows the potential of SARS-CoV-2 to cause movement disorders in the setting of COVID-19 induced DKA. 

COVID-19 and diabetes mellitus: from pathophysiology to clinical management

Diabetic Ketoacidosis in COVID-19: Unique Concerns and Considerations. The Journal of clinical endocrinology and metabolism

COVID-19: the endocrine opportunity in a pandemic

Defining and characterising diabetic ketoacidosis in adults. Diabetes research and clinical practice

Spectrum of hyperosmolar hyperglycaemic state in neurology practice

Diabetic striatopathy": clinical presentations, controversy, pathogenesis, treatments, and outcomes. Scientific reports

Neurological and Neuropsychiatric Impacts of COVID-19 Pandemic. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques

Diabetic striatal disease: clinical presentation, neuroimaging, and pathology. Internal medicine

Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report. Nat Metab

Type 1 diabetes triggered by covid-19 pandemic: A potential outbreak? Diabetes research and clinical practice

Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. Diabetes research and clinical practice

Viral infections in type 1 diabetes mellitus--why the beta cells?

The striatum is the most vulnerable region in the brain to mitochondrial energy compromise: a hypothesis to explain its specific vulnerability

Diabetic striatopathy" and ketoacidosis: Report of two cases and review of literature. Diabetes research and clinical practice

Diffusion-weighted and gradient echo magnetic resonance findings of hemichorea-hemiballismus associated with diabetic hyperglycemia: a hyperviscosity syndrome? Archives of neurology

SARS-CoV-2 infects brain astrocytes of COVID-19 patients and impairs neuronal viability